anemodeanin a has been researched along with Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Y; Guan, YD; Jiang, SL; Wen, M; Xiao, SS; Xu, XJ; Yu, P; Zhang, Y | 1 |
| Chen, S; Fan, S; Feng, M; He, W; Huang, K; Ma, J; Mo, J; Wang, J; Wang, Q; Xie, Z; Zhao, C | 1 |
2 other study(ies) available for anemodeanin a and Breast Neoplasms
| Article | Year |
|---|---|
Suppression of eEF-2K-mediated autophagy enhances the cytotoxicity of raddeanin A against human breast cancer cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Chloroquine; Down-Regulation; Elongation Factor 2 Kinase; Female; Heterocyclic Compounds, 3-Ring; Humans; Proto-Oncogene Proteins c-akt; Saponins; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
Raddeanin A suppresses breast cancer-associated osteolysis through inhibiting osteoclasts and breast cancer cells.
Topics: Animals; Blotting, Western; Bone Resorption; Breast Neoplasms; Cell Survival; Female; Humans; In Situ Nick-End Labeling; Mice; Mice, Inbred C57BL; Osteoclasts; Osteolysis; Saponins | 2018 |